CX3CR1 and neoplasm: Analysis of MC38 tumor-bearing mice treated with the Bpmel-SIY-OVAII cell adjuvant revealed a sustained increase in the proportion of CD27− CX3CR1+ and CD62L− CD44+ effector CD8+ T cells in the DLN as well as more significant infiltration of CD8+ T cells in the tumor site (Fig. S3, A–C) (Zwijnenburg et al., 2023; Yan et al., 2018; Gerlach et al., 2016).